UK Markets close in 3 hrs 29 mins

iShares $ Corp Bond ETF USD Dist (LQDA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.78+0.17 (+3.03%)
At close: 04:00PM EDT
6.10 +0.32 (+5.53%)
Pre-market: 08:00AM EDT
Sign in to post a message.
  • B
    Bruno
    The 4 analysts offering 12-month price forecasts for Liquidia Corp have a median target of 12.50, with a high estimate of 16.00 and a low estimate of 6.00.
  • S
    ST
    Inside buy again: Insider Caligan Partners LP reports buying 221,104 shares of $LQDA for a total cost of $1,301,472.56
  • S
    ST
    May 13, 2022, 06:28 AM
    A
    A

    In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $16.00. The company’s shares closed last Thursday at $4.66.
  • S
    ST
    Liquidia gains as PTAB hearing in United Therapeutics patent disputes nears conclusion
  • A
    Avi8tor
    Tyvaso DPI’s delivery device, along with the clinical results from BREEZE, may facilitate the introduction of inhaled treprostinil earlier in the clinical course of PAH for appropriate patients;

    Doses of Tyvaso DPI above the current recommended dose of nebulized Tyvaso (9-12 breaths four times daily) were well tolerated, potentially allowing for titration to higher dose levels without resulting in prolonged treatment sessions;

    A simplified dosing regimen could potentially increase patient compliance; and

    Tyvaso DPI has a pharmacokinetic (PK) profile comparable to nebulized Tyvaso, such that patients will not have to use more drug than nebulized Tyvaso to get the same treprostinil blood concentration or treatment effect.

    We’re thrilled that this manuscript builds on earlier data presented at the European Respiratory Society’s 2021 International Congress, with additional long-term follow-up data that continues to show a strong safety profile for patients transitioning from nebulized Tyvaso to Tyvaso DPI,” said Peter Smith, PharmD, Vice President, Product Development, at United Therapeutics. “The optional extension phase is still ongoing, and we’ve accrued over 71 patient-years of experience with Tyvaso DPI.”

    Source:https://ir.unither.com/news/press-releases/press-release-details/2022/United-Therapeutics-Announces-the-Publication-of-Tyvaso-DPI-BREEZE-Clinical-and-Long-term-Data-in-the-Journal-Pulmonary-Circulation/default.aspx
  • B
    Bruno
  • n
    nomdguer
    Interesting that LQDA board did not wait for a “good news bump” before announcing a huge dilution. Perhaps because they know that there is no good news on the horizon . . .? Pity for those banking on this speculative play—a company without any marketed product, and a valuation that is a multiple of hopes and dreams.
  • B
    BuyMNKD
    If LQDA mgmt cuts all the staff and turns the thermostat down in the winter, they may have cash left come 2028 when they can start manufacturing Yutrepia.
  • S
    ST
    “Caligan Partners LP, or Caligan, our largest stockholder, and Paul Manning, a member of our board of directors, have indicated interests in purchasing up to an aggregate of $11 million of shares of our common stock in this offering at the public offering price per share.”
  • T
    Tony
    $MNKD conversation
    United Therapeutics $uthr Loses Process-Patent Ruling in Liquidia $lqda Case
    https://news.bloomberglaw.com/ip-law/united-therapeutics-loses-process-patent-ruling-in-liquidia-case
  • S
    ST
    Target still 16
  • d
    davida
    OUCH...those attorney fees must be mounting up..... need to raise cash
  • C
    Cubicle_98
    $IBRX conversation
    Earl … 18 of 273 biotechs are green in the contest so far this year:
    $cmpi
    $srra
    $vygr
    $mirm
    $cfrx
    $veru
    $optn
    $fenc
    $adma
    $mdvl
    $eigr
    $vcnx
    $capr
    $icpt
    $lqda
    $fusn
    $otic
    $azyo
  • S
    ST
    Needham stick Buy for lqda
  • T
    TW
    $5.10? Ouch. That's less than Rusty Shundler paid. Just shows that he was banking on a summary judgment.
  • L
    Long Term
    How did the trial go?
  • L
    Long Term
    Looks like they are not expecting any good news in the next 3 to 6 months - but this doesn't mean 2023 won't be much better.
  • n
    nomdguer
    Viewing the YTD trading range confirms that EVERY SHARE purchased by anyone YTD was at a price above what the newly-issued shares will be sold for . . . So any one of you who bought LQDA this year becomes a loser. Not to mention that, based on existing float, the number of shares proposed to be issued, plus the over-subscription, will dilute your interest in the company by a cool 33%.

    A classic “lose-lose” if ever there was one.
  • S
    ST
    Bought back the 50k shares sold last week
  • R
    Real Mango3
    $MNKD conversation
    Bloomberg Law just released a piece about $UTHR’s recent failure in court against $lqda treprostinil dpi:
    (Part 1) By Christopher Yasiejko
    (Bloomberg Law) -- United Therapeutics Corp. can’t lean on a presumption that the Korean manufacturer of Liquidia Technologies Inc.’s Yutrepia prepares its active ingredient using a process claimed in one of three patents at issue in an infringement case over competing treatments for high blood
    pressure in the lungs, a federal judge in Delaware ruled. Judge Richard G. Andrews denied UTC’s request that he apply a legal presumption that Yutrepia, a rival to UTC’s Tyvaso, is made using the process claimed in the patent, according to an opinion Tuesday in the U.S. District Court for the District of Delaware.